独立投资银行咨询公司Evercore列出2026首选股名单，微软与赛富时位居前两名。 责任编辑：张俊 SF065 独立投资银行咨询公司Evercore列出2026首选股名单，微软与赛富时位居前两名。 责任编辑：张俊 SF065 ...

Group 1 - John Weinberg is the Chairman and CEO of Evercore, a position he has held for nearly 4 years [1] - Prior to his current role, he served as Co-Chairman of the Board and co-CEO since July 2020, overseeing significant growth at Evercore [1] - John Weinberg has a background as Vice Chairman of Goldman Sachs and Head of Investment Banking before joining Evercore in November 2016 [1]

Summary of Evercore Conference Call Company Overview - **Company**: Evercore - **Position**: Chairman and CEO John Weinberg has been in this role for nearly four years, overseeing significant growth and expansion in various sectors and regions [1][3] Key Points and Arguments Growth and Expansion - Evercore has significantly expanded its client footprint and market presence over the past five to six years, particularly in Europe and the sponsor business [3][4] - The firm is now ranked third globally in total advisory revenues, indicating a strong improvement in market share [5] - The brand recognition of Evercore has increased, with more clients approaching the firm without solicitation [6] Strategic Priorities - The focus for the next three to five years includes expanding client reach, broadening product offerings, and investing in high-growth areas such as software, AI, FinTech, and Biotech [7] - The acquisition of Robey Warshaw is seen as a strategic move to enhance Evercore's presence in Europe, particularly in the UK [9] Market Conditions and Client Sentiment - There is a positive sentiment in boardrooms, with management teams open to exploring various strategic options due to improved financing conditions and a more favorable regulatory environment [13][14] - Private equity sponsors are under pressure to execute deals, leading to increased activity in the market [16][17] European Market Outlook - Evercore has established a strong market position in Europe, with record activity levels and a focus on building long-term relationships [19][20] - Recent successful deals, such as the sale of Kering's beauty business to L'Oréal, highlight the firm's growing influence in the region [20] Advisory and ECM Market Trends - The advisory business is expected to continue its upward trajectory, with a strong pipeline of deals anticipated in 2024 and beyond [24][25] - The equity capital markets (ECM) segment is also showing signs of strength, particularly in IPOs and healthcare-related activities [27][28] Restructuring and Liability Management - The restructuring business remains robust, with an increase in larger traditional assignments and a strong backlog [41][42] - The perception of restructuring as a liability management tool is evolving, leading to more significant engagements [44] Financial Management and Capital Return - Evercore is focused on balancing growth investments with margin improvement, aiming to reduce the compensation ratio while managing non-comp expenses [45][46] - The firm has been actively repurchasing shares and plans to continue returning capital to shareholders [47] Future Outlook - The firm is optimistic about 2025 and 2026, with a strong talent pool and a collaborative culture that supports growth [48] Additional Important Insights - The firm has seen a record pace in its secondaries business, with no signs of slowing down, indicating strong client relationships and market acceptance of its products [33][34] - There is no cannibalization between GP and LP secondary businesses, as both serve distinct needs for sponsors [37][38] This summary encapsulates the key insights from the Evercore conference call, highlighting the company's growth strategies, market conditions, and future outlook.

Core Insights - Evercore has received its Arranging License from the Capital Markets Authority in Saudi Arabia and is opening an office in Riyadh to provide independent advisory services [1][2] - The Riyadh office will be led by Mohammed Aldekmary, who has extensive experience in investment banking and government advisory [3] - The expansion into Saudi Arabia is part of Evercore's growth strategy in the Middle East, which is identified as a priority area for the firm [2] Company Overview - Evercore is a global independent investment banking advisory firm, founded in 1995, with headquarters in New York and offices in major financial centers worldwide [4] - The firm specializes in providing strategic and financial advice on mergers and acquisitions, restructurings, and capital structure, as well as raising public and private capital [4] - Evercore also offers equity research, sales, agency trading execution, and wealth management services to high-net-worth and institutional investors [4]

Core Viewpoint - Evercore Inc. (EVR) has demonstrated strong stock performance, with shares rising 37.9% over the past six months, outperforming both the industry and the S&P 500 Index [1][10] Price Performance - EVR's stock performance has surpassed that of peers Moelis & Company (12.8% increase) and Stifel Financial Corp. (31% increase) during the same period [1][10] Factors Supporting Performance - Strong Investment Banking Franchise: The company benefits from a solid business foundation, with its Investment Banking segment showing a healthy CAGR of 8.6% from 2017 to 2024, supported by a recovery in global M&A markets in 2024 [4][5][7] - Healthy Liquidity Position: As of September 30, 2025, cash and cash equivalents were $851.9 million, with total investment securities and certificates of deposit at $1.6 billion, indicating a strong liquidity position [8][11] - Stable Capital Return Policy: The company raised its quarterly dividend by 5% to 84 cents per share in April 2025, with a 10.4% CAGR in annual dividends over the past six years [12][13] - Strong Return on Equity (ROE): EVR's trailing 12-month ROE stands at 29.56%, significantly above the industry average of 15.87% [14] Near-Term Challenges - Weak Investment Management Performance: The Investment Management segment has faced challenges, contributing a small share of total revenues and experiencing subdued growth due to restructuring [15] - Rising Expense Base: The company's expenses have increased at a CAGR of 9.8% over the past seven years, with higher employee compensation and travel costs expected to constrain profitability [16] Earnings Estimates - The Zacks Consensus Estimate for earnings per share has been revised upward to $13.53 for 2025, indicating projected growth of 43.6% [17][18] Valuation - EVR stock is currently trading at a trailing P/E ratio of 17.9X, higher than the industry average of 14.6X, suggesting it may be considered expensive relative to peers [19] Long-Term Outlook - Evercore's strong advisory momentum, solid liquidity, and consistent capital distribution strategy are expected to support long-term performance, particularly in an improving M&A environment [21]

Core Insights - Mapi Pharma Ltd. is participating in the 8th Annual Evercore Annual Healthcare Conference to explore partnerships for its innovative long-acting depot injectable treatments [1][2] Company Overview - Mapi Pharma is a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting depot injectable treatments [1][7] - The company has a strong intellectual property (IP) portfolio and utilizes extended-release depot technologies for lifecycle management products across multiple therapeutic areas [3][7] Product Pipeline - Mapi's lead product, GA Depot, is under a commercialization agreement for the treatment of Relapsing Forms of Multiple Sclerosis (RMS) and is currently under FDA review following successful Phase 3 results [3][7] - The development pipeline includes an injectable version of cariprazine for schizophrenia, bipolar I, and major depression disorders, with patient enrollment in a Phase I/II study recently initiated [4][7] - Other products in development include Depot formulations for Huntington's disease, tardive dyskinesia, and hormone receptor-positive early breast cancer [6][7] Research and Development Capabilities - Mapi has a dedicated R&D team and state-of-the-art GMP approved manufacturing facility, enabling efficient development of depot products [5][7] - The company is positioned to co-develop depot drugs with partners interested in long-acting injectable lifecycle management versions of their molecules [6][7]

Core Insights - Krystal Biotech, Inc. will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami, with CEO Krish S. Krishnan scheduled for a fireside chat at 10:00 am ET [1] - A webcast of the presentation will be available on the Company's website starting at the same time [2] Company Overview - Krystal Biotech, Inc. is a global biotechnology company focused on genetic medicines for diseases with high unmet medical needs, with its first product, VYJUVEK®, being the first-ever redosable gene therapy approved in the US, Europe, and Japan for dystrophic epidermolysis bullosa [3] - The Company is advancing a pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3]

Core Points - Merck will participate in the 8th Annual Evercore ISI HealthCONx Conference on December 2, 2025, featuring Chirfi Guindo and Dr. Eliav Barr [1] - A live audio webcast of the presentation will be available for investors, analysts, and the public [2] - Merck aims to be a leading research-intensive biopharmaceutical company, focusing on innovative health solutions and a diverse workforce [3] Company Overview - Merck, known as MSD outside the U.S. and Canada, has over 130 years of experience in developing important medicines and vaccines [3] - The company is committed to advancing clinical research in hematology and has an expanding pipeline of investigational candidates [7]

Core Points - An affiliate of Elliott Investment Management, Amber Energy, won a court-ordered auction for control of Citgo Petroleum Corp., which is considered Venezuela's most valuable foreign asset [1][2] - The US District Judge Leonard Stark approved Amber Energy's bid of $5.89 billion, stating it was the highest and best offer after a lengthy auction process [2][3] - The judge emphasized that the Amber bid provided the best combination of price and certainty of closing, and it was neither grossly inadequate nor manifestly unjust [3] Financial Implications - Following the announcement, PDVSA bonds due in 2020, which are backed by shares in a PDV Holding affiliate, increased in value, trading slightly above par [4] - The deal with Amber will allow bondholders to be paid off with $1.68 billion in cash at the closing of the sale, as they will release their pledge against the company [4] Company Operations - Citgo operates refineries, pipelines, terminals, and fuel distribution channels in the US, and is a subsidiary of PDV Holding, which is controlled by Venezuela's political opposition [7] - The political opposition represents PDVSA in US courts due to the lack of recognition of President Nicolas Maduro's government by the US [7] Legal Context - The auction process has faced controversy, with Gold Reserve Ltd. attempting to disqualify the judge and special master, claiming favoritism towards Amber [8] - Despite these claims, Judge Stark and Special Master Robert Pincus were not disqualified, and the auction process continues with a deadline for last objections set for November 28 [6][9] Historical Background - The legal battle over Citgo is part of a long-standing issue involving various creditors, including Canadian miner Crystallex International Corp. and US driller ConocoPhillips Co., seeking compensation for losses from the nationalization of their assets in Venezuela [10]

Core Insights - Halozyme Therapeutics, Inc. will present at the 8th Annual Evercore Healthcare Conference on December 2, 2025, at 10:20 am PT / 1:20 pm ET, hosted by Dr. Helen Torley, the president and CEO [1] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to enhance patient experiences and outcomes for both emerging and established therapies [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs, improving convenience and reducing treatment burden [4] - ENHANZE® has impacted over one million patients through ten commercialized products across more than 100 global markets, with partnerships involving major pharmaceutical companies such as Roche, Takeda, and Pfizer [4] Technology Development - Halozyme is developing Hypercon™, a microparticle technology aimed at hyper-concentration of drugs and biologics, which is expected to reduce injection volume while expanding at-home and healthcare provider administration opportunities [5] - The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson and Eli Lilly, enhancing the company's drug delivery capabilities [5] Product Portfolio - The company also develops drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence, with proprietary products like Hylenex® and XYOSTED® [6] - Halozyme has ongoing development programs in collaboration with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. [6] Corporate Information - Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey; Minnetonka, Minnesota; and Boston, Massachusetts [7]